Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kassiou

Showing results (21-30 of 231) with videos related to

Pageof 24
Sort By:
Current Pharmaceutical Design|February 3, 2007
Imaging sigma receptors: applications in drug developmentThomas Lee Collier, Rikki N Waterhouse, Michael Kassiou
Journal of Medicinal Chemistry|January 13, 2009
The translocator protein (18 kDa): central nervous system disease and drug designAlana M Scarf, Lars M Ittner, Michael Kassiou
Bioorganic & Medicinal Chemistry Letters|June 1, 2013
The development of CNS-active LRRK2 inhibitors using property-directed optimisationMadeline E Kavanagh, Munikumar Reddy Doddareddy, Michael Kassiou
ACS Chemical Neuroscience|June 3, 2017
Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACAMitchell Longworth, Mark Connor, Samuel D Banister, et al.
Scientific Reports|June 11, 2020
Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brainDannielle H Upton, Kata Popovic, Roger Fulton, et al.
Pharmacology & Therapeutics|June 18, 2022
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?Elijah Genetzakis, Jayson Gilchrist, Michael Kassiou, et al.
Pharmacology & Therapeutics|March 22, 2015
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implicationsRamzi Abbassi, Terrance G Johns, Michael Kassiou, et al.
Current Pharmaceutical Design|January 29, 2016
The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) DiseasesCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
11-{[2-(3-Fluoro-phen-yl)eth-yl](meth-yl)amino}-penta-cyclo-[5.4.0.0.0.0]undecan-8-oneSamuel D Banister, Jack K Clegg, Raphy Hanani, et al.
Physics in Medicine and Biology|November 3, 2005
Small animal SPECT and its place in the matrix of molecular imaging technologiesSteven R Meikle, Peter Kench, Michael Kassiou, et al.
Pageof 24

Showing results (21-30 of 231) with videos related to

Sort By:
Pageof 24
Current Pharmaceutical Design|February 3, 2007
Imaging sigma receptors: applications in drug developmentThomas Lee Collier, Rikki N Waterhouse, Michael Kassiou
Journal of Medicinal Chemistry|January 13, 2009
The translocator protein (18 kDa): central nervous system disease and drug designAlana M Scarf, Lars M Ittner, Michael Kassiou
Bioorganic & Medicinal Chemistry Letters|June 1, 2013
The development of CNS-active LRRK2 inhibitors using property-directed optimisationMadeline E Kavanagh, Munikumar Reddy Doddareddy, Michael Kassiou
ACS Chemical Neuroscience|June 3, 2017
Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACAMitchell Longworth, Mark Connor, Samuel D Banister, et al.
Scientific Reports|June 11, 2020
Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brainDannielle H Upton, Kata Popovic, Roger Fulton, et al.
Pharmacology & Therapeutics|June 18, 2022
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?Elijah Genetzakis, Jayson Gilchrist, Michael Kassiou, et al.
Pharmacology & Therapeutics|March 22, 2015
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implicationsRamzi Abbassi, Terrance G Johns, Michael Kassiou, et al.
Current Pharmaceutical Design|January 29, 2016
The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) DiseasesCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 19, 2011
11-{[2-(3-Fluoro-phen-yl)eth-yl](meth-yl)amino}-penta-cyclo-[5.4.0.0.0.0]undecan-8-oneSamuel D Banister, Jack K Clegg, Raphy Hanani, et al.
Physics in Medicine and Biology|November 3, 2005
Small animal SPECT and its place in the matrix of molecular imaging technologiesSteven R Meikle, Peter Kench, Michael Kassiou, et al.
Pageof 24